- Lab Tests
- Health Corner
BRILINTA 90MG contains ticagrelor which belongs to the group of medicines called antiplatelet agents. It is used to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor stops clumping of blood cells called platelets, which is responsible for clot formation in diseased blood vessels of heart and brain and thus reduces the chances of a blood clot formation. It can be taken with or without food.
The most common side effect of taking this medicine are bleeding and bruising. Avoid concomitant use of ticagrelor and other oral anticoagulants like heparin or warfarin, as it may increase the risk of side effects. Do not take this medicine if you are suffering from any bleeding disorders or liver problems. This medicine is not recommended for use in pregnant or breastfeeding women and in children aged below 18 years.
Ticagrelor is a potent P2Y12 receptor antagonist. In diseased blood vessels, platelets can form thrombus (blood clot) by binding to the arterial surface. Activated platelets produces ADP3 which binds to P2Y12 receptor and propagates thrombus formation. Ticagrelor reversibly binds to P2Y12 receptor instead of ADP3 and prevents the signal transduction and platelet activation, that can lead to blood clot formation.
Take this medicine as directed by your physician. It can be taken with or without food. Your doctor will decide the correct dose for you depending upon your condition. Swallow the medicine with a glass of water. If you have trouble in swallowing the medicine, you can crush it and mix with half a glass of water. Stir and drink immediately. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.
Feeling sick (nausea):
Try taking this medicine with, or just after meal. Stick to simple meals. Do not eat rich or spicy food.
Eat fibre rich foods like fresh fruit, vegetables and cereals. Drink plenty of water. Exercise more regularly.
Drink lots of fluids, such as water or juice, to avoid dehydration. Do not take any medicines without speaking to a doctor.
Apply hot or cold-water bag on your head. Take rest in a quiet and dark room. Drink tea or coffee.
BRILINTA 90MG is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your doctor.
BRILINTA 90MG is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your doctor.
Do not drive or operate any machines if your ability is affected by this medicine.
Avoid consumption of alcohol while taking this medicine.
Do not take BRILINTA 90MG if you are suffering from severe liver disease. Consult your doctor for advice.
Do not take this medicine if you are allergic to Ticagrelor.
BRILINTA 90MG should be taken with caution in patients with asthma or other lung problems or breathing difficulties. Consult your doctor for advice.
BRILINTA 90MG should be taken with caution in patients with abnormal heart rate. Consult your doctor for advice.
Talk to your doctor before taking this medicine, if you:
Talk to your doctor, if you are taking,
|Pharmacological Category||:|| |
Antiplatelet agent, P2Y12 receptor antagonist
|Therapeutic Indication||:||Heart attack and stroke|
Store at room temperature and keep out of reach of children.
1. Keith A.A. Fox, Harvey D. White, Bernard J. Gersh and Lionel H. Opie. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics and Chronic Anticoagulants. Drugs for the heart. 8th Edition. 2013. Page - 351-352.
2. Gerald G. Briggs, Roger K. Freeman. T. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation, Tenth Edition. 2015. Page – 3799-3800.
3. Jolanta M Siller-Matula, Bernd Jilma. Ticagrelor: from discovery to Phase III clinical trial. NIH National Library of Medicine, National center of Biotechnology information. November 2010. [Accessed 27th October 2020] https://pubmed.ncbi.nlm.nih.gov/21142630/
4. Dominick J. Angiolillo , George D. Dangas. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention – TWILIGHT. American college of cardiology. March 2020. [Accessed 27th October 2020] https://www.acc.org/latest-in-cardiology/clinical-trials/2019/09/24/23/30/twilight
5. AstraZeneca AB; Electronic Medicines Compendium (EMC) [Revised on September 2019] Accessed 27th October 2020] https://www.medicines.org.uk/emc/files/pil.5767.pdf
6. AstraZeneca AB; Electronic Medicines Compendium (EMC) [Revised on September 2019] Accessed 27th October 2020] https://www.medicines.org.uk/emc/files/pil.7606.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.